Journal of Clinical Oncology · 2015 · 161 citations · 20 references
MedicineOncologyCancer EpidemiologyClinical EpidemiologySepsisPrognostic AssessmentToxicity GradingClinical Stability AssessmentMulticenter ValidationOrgan Dysfunction PredictionPrognostic CriteriaPrognostic Score ValidationPrognostic VariablesProspective Cohort DataStress Hyperglycemia
PURPOSE: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections. PATIENTS AND METHODS: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We integrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE. RESULTS: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC). CONCLUSION: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes.
20
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz et al. · Clinical Infectious Diseases · 2011 · 3.4K citations
Peter Peduzzi, John Concato, Alvan R. Feinstein et al. · Journal of Clinical Epidemiology · 1995 · 2.1K citations · Full text
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Nicole M. Kuderer, David C. Dale, Jeffrey Crawford et al. · Cancer · 2006 · 1.2K citations · Full text